BIOTRON LIMITED - Announcements

Market Cap $17.14M Add to my watchlist

Healthcare Biotechnology

Biotron Limited is an Australia-based biotechnology company. The Company is primarily... Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BIT	Response to ASX Aware Query	PRICE SENSITIVE	25/09/24	1.5MB	Share
BIT	BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL	PRICE SENSITIVE	06/09/24	540.68KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	30/08/24	1.41MB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	1.01MB	Share
BIT	BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives	PRICE SENSITIVE	19/06/24	711.16KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/24	1MB	Share
BIT	POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV	PRICE SENSITIVE	05/04/24	670.99KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	27/03/24	453.67KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/24	603.88KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	277.88KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	1.03MB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	29/09/23	712.55KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	11/09/23	665.15KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	25/08/23	1.05MB	Share
BIT	COMPLETION OF PHASE 2 COVID CLINICAL TRIAL	PRICE SENSITIVE	16/08/23	312.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	475.77KB	Share
BIT	Second Site Approved for Phase 2 Covid-19 Trial	PRICE SENSITIVE	12/05/23	89.11KB	Share
BIT	Commencement Phase 2 Covid-19 Clinical Trial	PRICE SENSITIVE	04/05/23	144.72KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	1.01MB	Share
BIT	Completion of Phase 2 HIV-1 Clinical Trials	PRICE SENSITIVE	09/03/23	403.58KB	Share
BIT	International Presentation of BIT225 COVID-19 Data	PRICE SENSITIVE	21/02/23	824.33KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/23	794.46KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	436.71KB	Share
BIT	Rights Issue Closed	PRICE SENSITIVE	24/11/22	174.24KB	Share
BIT	Supplementary Prospectus	PRICE SENSITIVE	24/11/22	139.65KB	Share
BIT	$1.43M R&D rebate received	PRICE SENSITIVE	18/11/22	148.2KB	Share
BIT	Commencement of Rights Trading - BITRC	PRICE SENSITIVE	31/10/22	128.29KB	Share
BIT	Prospectus	PRICE SENSITIVE	27/10/22	683.43KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	27/10/22	190.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/10/22	422.98KB	Share
BIT	Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	04/10/22	181.16KB	Share
BIT	Bit225 Covid-19 Human Study Commenced	PRICE SENSITIVE	14/09/22	175.41KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	23/08/22	154.11KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	19/08/22	670.98KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	1.04MB	Share
BIT	POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM	PRICE SENSITIVE	30/05/22	130.47KB	Share
BIT	BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PRICE SENSITIVE	02/05/22	353.01KB	Share
BIT	Quarterly Cash Flow Report Appendix 4C	PRICE SENSITIVE	26/04/22	250.36KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	26/04/22	137.32KB	Share
BIT	$1.56M R&D Rebate Received	PRICE SENSITIVE	05/04/22	147.99KB	Share
BIT	BIT225 Effectiveness Against COVID-19 in Animals	PRICE SENSITIVE	17/03/22	214.51KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/22	630.82KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	135.98KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	248.82KB	Share
BIT	BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PRICE SENSITIVE	25/11/21	594.07KB	Share
BIT	COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS	PRICE SENSITIVE	01/11/21	157.65KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/10/21	140.11KB	Share
BIT	Quarterly Cash Flow Report	PRICE SENSITIVE	28/10/21	155.44KB	Share
BIT	Full Year Statutory Accounts and Preliminary Final Report	PRICE SENSITIVE	27/08/21	951.58KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	30/07/21	141.42KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/21	155.38KB	Share
BIT	$1.4M R&D Tax Rebate	PRICE SENSITIVE	29/04/21	117.13KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/04/21	140.53KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/21	155.05KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/21	447.04KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/01/21	141.92KB	Share
BIT	Quarterly Cashflow Report	PRICE SENSITIVE	29/01/21	155.26KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/10/20	143.32KB	Share
BIT	Quarterly Cashflow Report	PRICE SENSITIVE	29/10/20	155.86KB	Share
BIT	Biotron Compounds Show Activity Against SARS-CoV-2 Virus	PRICE SENSITIVE	07/09/20	141.9KB	Share
BIT	Trading Halt	PRICE SENSITIVE	03/09/20	114.48KB	Share
BIT	Pause in Trading	PRICE SENSITIVE	03/09/20	115.52KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	27/08/20	677.29KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/07/20	141.46KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/20	155.99KB	Share
BIT	BIT225 Reverses HIV-Induced Immune Evasion	PRICE SENSITIVE	06/07/20	669.54KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	23/04/20	144.47KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	23/04/20	164.52KB	Share
BIT	R&D Tax Refund Received	PRICE SENSITIVE	19/03/20	111.09KB	Share
BIT	BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS	PRICE SENSITIVE	12/03/20	747.75KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	1.73MB	Share
BIT	Biotron to Test its Compounds Against Coronavirus	PRICE SENSITIVE	06/02/20	226.09KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/20	702.24KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	23/01/20	620.57KB	Share
BIT	Biotron Secures $5.1 Million Underwriting Agreement	PRICE SENSITIVE	08/11/19	228.04KB	Share
BIT	Presentation to Investors	PRICE SENSITIVE	31/10/19	980.29KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/19	702.34KB	Share
BIT	Appointment of International Advisory Board for BIT225	PRICE SENSITIVE	01/10/19	125.89KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	29/08/19	1.08MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/19	702.33KB	Share
BIT	Presentation at BIO 2019	PRICE SENSITIVE	07/06/19	6.64MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	11/04/19	705.54KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	20/02/19	1.72MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	18/01/19	690.62KB	Share
BIT	PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA	PRICE SENSITIVE	28/11/18	2.91MB	Share
BIT	Response to ASX aware letter	PRICE SENSITIVE	30/10/18	614.87KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/18	89.58KB	Share
BIT	Biotron Secures $4.7 Million Underwriting Agreement	PRICE SENSITIVE	17/10/18	34.77KB	Share
BIT	$1.07 million R&D Tax Incentive Received	PRICE SENSITIVE	15/10/18	41.34KB	Share
BIT	Significant Immunological Outcomes in BIT225 HIV-1 Trial	PRICE SENSITIVE	28/09/18	406.97KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	29/08/18	2.02MB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	07/08/18	382.37KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	11/07/18	686.82KB	Share
BIT	Response to ASX Appendix 4C Query	PRICE SENSITIVE	10/05/18	986.36KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	10/05/18	630.61KB	Share
BIT	Prospectus	PRICE SENSITIVE	10/05/18	975.11KB	Share
BIT	Renounceable Rights Issue	PRICE SENSITIVE	10/05/18	5.54MB	Share
BIT	Trading Halt	PRICE SENSITIVE	08/05/18	67.26KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/18	686.08KB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	06/04/18	456.15KB	Share

BIT Response to ASX Aware Query
25/09/24	PRICE SENSITIVE	1.5MB	Share
BIT BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL
06/09/24	PRICE SENSITIVE	540.68KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
30/08/24	PRICE SENSITIVE	1.41MB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	1.01MB	Share
BIT BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
19/06/24	PRICE SENSITIVE	711.16KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
26/04/24	PRICE SENSITIVE	1MB	Share
BIT POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
05/04/24	PRICE SENSITIVE	670.99KB	Share
BIT Response to ASX Price Query
27/03/24	PRICE SENSITIVE	453.67KB	Share
BIT Half Yearly Report and Accounts
27/02/24	PRICE SENSITIVE	603.88KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	277.88KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	1.03MB	Share
BIT Response to ASX Price Query
29/09/23	PRICE SENSITIVE	712.55KB	Share
BIT Response to ASX Price Query
11/09/23	PRICE SENSITIVE	665.15KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
25/08/23	PRICE SENSITIVE	1.05MB	Share
BIT COMPLETION OF PHASE 2 COVID CLINICAL TRIAL
16/08/23	PRICE SENSITIVE	312.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	475.77KB	Share
BIT Second Site Approved for Phase 2 Covid-19 Trial
12/05/23	PRICE SENSITIVE	89.11KB	Share
BIT Commencement Phase 2 Covid-19 Clinical Trial
04/05/23	PRICE SENSITIVE	144.72KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	1.01MB	Share
BIT Completion of Phase 2 HIV-1 Clinical Trials
09/03/23	PRICE SENSITIVE	403.58KB	Share
BIT International Presentation of BIT225 COVID-19 Data
21/02/23	PRICE SENSITIVE	824.33KB	Share
BIT Half Yearly Report and Accounts
17/02/23	PRICE SENSITIVE	794.46KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	436.71KB	Share
BIT Rights Issue Closed
24/11/22	PRICE SENSITIVE	174.24KB	Share
BIT Supplementary Prospectus
24/11/22	PRICE SENSITIVE	139.65KB	Share
BIT $1.43M R&D rebate received
18/11/22	PRICE SENSITIVE	148.2KB	Share
BIT Commencement of Rights Trading - BITRC
31/10/22	PRICE SENSITIVE	128.29KB	Share
BIT Prospectus
27/10/22	PRICE SENSITIVE	683.43KB	Share
BIT Renounceable Issue
27/10/22	PRICE SENSITIVE	190.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/10/22	PRICE SENSITIVE	422.98KB	Share
BIT Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
04/10/22	PRICE SENSITIVE	181.16KB	Share
BIT Bit225 Covid-19 Human Study Commenced
14/09/22	PRICE SENSITIVE	175.41KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
23/08/22	PRICE SENSITIVE	154.11KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
19/08/22	PRICE SENSITIVE	670.98KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	1.04MB	Share
BIT POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
30/05/22	PRICE SENSITIVE	130.47KB	Share
BIT BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
02/05/22	PRICE SENSITIVE	353.01KB	Share
BIT Quarterly Cash Flow Report Appendix 4C
26/04/22	PRICE SENSITIVE	250.36KB	Share
BIT Quarterly Activities Report
26/04/22	PRICE SENSITIVE	137.32KB	Share
BIT $1.56M R&D Rebate Received
05/04/22	PRICE SENSITIVE	147.99KB	Share
BIT BIT225 Effectiveness Against COVID-19 in Animals
17/03/22	PRICE SENSITIVE	214.51KB	Share
BIT Half Yearly Report and Accounts
23/02/22	PRICE SENSITIVE	630.82KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	135.98KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	248.82KB	Share
BIT BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS
25/11/21	PRICE SENSITIVE	594.07KB	Share
BIT COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
01/11/21	PRICE SENSITIVE	157.65KB	Share
BIT Quarterly Activities Report
28/10/21	PRICE SENSITIVE	140.11KB	Share
BIT Quarterly Cash Flow Report
28/10/21	PRICE SENSITIVE	155.44KB	Share
BIT Full Year Statutory Accounts and Preliminary Final Report
27/08/21	PRICE SENSITIVE	951.58KB	Share
BIT Quarterly Activities Report
30/07/21	PRICE SENSITIVE	141.42KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
30/07/21	PRICE SENSITIVE	155.38KB	Share
BIT $1.4M R&D Tax Rebate
29/04/21	PRICE SENSITIVE	117.13KB	Share
BIT Quarterly Activities Report
28/04/21	PRICE SENSITIVE	140.53KB	Share
BIT Appendix 4C - quarterly
28/04/21	PRICE SENSITIVE	155.05KB	Share
BIT Half Yearly Report and Accounts
23/02/21	PRICE SENSITIVE	447.04KB	Share
BIT Quarterly Activities Report
29/01/21	PRICE SENSITIVE	141.92KB	Share
BIT Quarterly Cashflow Report
29/01/21	PRICE SENSITIVE	155.26KB	Share
BIT Quarterly Activities Report
29/10/20	PRICE SENSITIVE	143.32KB	Share
BIT Quarterly Cashflow Report
29/10/20	PRICE SENSITIVE	155.86KB	Share
BIT Biotron Compounds Show Activity Against SARS-CoV-2 Virus
07/09/20	PRICE SENSITIVE	141.9KB	Share
BIT Trading Halt
03/09/20	PRICE SENSITIVE	114.48KB	Share
BIT Pause in Trading
03/09/20	PRICE SENSITIVE	115.52KB	Share
BIT Full Year Statutory Accounts
27/08/20	PRICE SENSITIVE	677.29KB	Share
BIT Quarterly Activities Report
29/07/20	PRICE SENSITIVE	141.46KB	Share
BIT Appendix 4C - quarterly
29/07/20	PRICE SENSITIVE	155.99KB	Share
BIT BIT225 Reverses HIV-Induced Immune Evasion
06/07/20	PRICE SENSITIVE	669.54KB	Share
BIT Quarterly Activities Report
23/04/20	PRICE SENSITIVE	144.47KB	Share
BIT Appendix 4C - quarterly
23/04/20	PRICE SENSITIVE	164.52KB	Share
BIT R&D Tax Refund Received
19/03/20	PRICE SENSITIVE	111.09KB	Share
BIT BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS
12/03/20	PRICE SENSITIVE	747.75KB	Share
BIT Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	1.73MB	Share
BIT Biotron to Test its Compounds Against Coronavirus
06/02/20	PRICE SENSITIVE	226.09KB	Share
BIT Appendix 4C - quarterly
24/01/20	PRICE SENSITIVE	702.24KB	Share
BIT Response to ASX Price Query
23/01/20	PRICE SENSITIVE	620.57KB	Share
BIT Biotron Secures $5.1 Million Underwriting Agreement
08/11/19	PRICE SENSITIVE	228.04KB	Share
BIT Presentation to Investors
31/10/19	PRICE SENSITIVE	980.29KB	Share
BIT Appendix 4C - quarterly
21/10/19	PRICE SENSITIVE	702.34KB	Share
BIT Appointment of International Advisory Board for BIT225
01/10/19	PRICE SENSITIVE	125.89KB	Share
BIT Full Year Statutory Accounts
29/08/19	PRICE SENSITIVE	1.08MB	Share
BIT Appendix 4C - quarterly
30/07/19	PRICE SENSITIVE	702.33KB	Share
BIT Presentation at BIO 2019
07/06/19	PRICE SENSITIVE	6.64MB	Share
BIT Appendix 4C - quarterly
11/04/19	PRICE SENSITIVE	705.54KB	Share
BIT Half Yearly Report and Accounts
20/02/19	PRICE SENSITIVE	1.72MB	Share
BIT Appendix 4C - quarterly
18/01/19	PRICE SENSITIVE	690.62KB	Share
BIT PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA
28/11/18	PRICE SENSITIVE	2.91MB	Share
BIT Response to ASX aware letter
30/10/18	PRICE SENSITIVE	614.87KB	Share
BIT Appendix 4C - quarterly
24/10/18	PRICE SENSITIVE	89.58KB	Share
BIT Biotron Secures $4.7 Million Underwriting Agreement
17/10/18	PRICE SENSITIVE	34.77KB	Share
BIT $1.07 million R&D Tax Incentive Received
15/10/18	PRICE SENSITIVE	41.34KB	Share
BIT Significant Immunological Outcomes in BIT225 HIV-1 Trial
28/09/18	PRICE SENSITIVE	406.97KB	Share
BIT Full Year Statutory Accounts
29/08/18	PRICE SENSITIVE	2.02MB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
07/08/18	PRICE SENSITIVE	382.37KB	Share
BIT Appendix 4C - quarterly
11/07/18	PRICE SENSITIVE	686.82KB	Share
BIT Response to ASX Appendix 4C Query
10/05/18	PRICE SENSITIVE	986.36KB	Share
BIT Response to ASX Price Query
10/05/18	PRICE SENSITIVE	630.61KB	Share
BIT Prospectus
10/05/18	PRICE SENSITIVE	975.11KB	Share
BIT Renounceable Rights Issue
10/05/18	PRICE SENSITIVE	5.54MB	Share
BIT Trading Halt
08/05/18	PRICE SENSITIVE	67.26KB	Share
BIT Appendix 4C - quarterly
24/04/18	PRICE SENSITIVE	686.08KB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
06/04/18	PRICE SENSITIVE	456.15KB	Share

REFRESH

1 2

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
2.0¢	2.0¢	1.9¢	$3.921K	205.5K

Buyers (Bids)

No.	Vol.	Price($)
3	776274	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	1861030	4

View Market Depth

No.	Vol.	Price($)
3	923643	0.019
10	1774771	0.018
8	927388	0.017
12	3734154	0.016
10	1205000	0.015

Price($)	Vol.	No.
0.019	53409	1
0.020	1861030	4
0.021	605263	2
0.022	997769	4
0.023	1449422	4

Last trade - 16.10pm 01/10/2024 (20 minute delay)


Last 2.0¢		Change 0.000 ( 2.63 %)
Open	High	Low	Volume
2.0¢	2.0¢	1.9¢	385004
Last updated 13.23pm 01/10/2024 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories